Prevention of Early Alzheimer’s Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study

Frontiers in Aging Neuroscience ◽

10.3389/fnagi.2020.00155 ◽

2020 ◽

Vol 12 ◽

Author(s):

I-Chen Li ◽

Han-Hsin Chang ◽

Chuan-Han Lin ◽

Wan-Ping Chen ◽

Tsung-Han Lu ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Hericium Erinaceus ◽

Early Alzheimer’S Disease ◽

Erinacine A

Download Full-text

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

The Lancet ◽

10.1016/s0140-6736(01)05623-9 ◽

2001 ◽

Vol 358 (9280) ◽

pp. 455-460 ◽

Cited By ~ 130

Author(s):

Willem A Van Gool ◽

Henry C Weinstein ◽

Philip K Scheltens ◽

Gerard JM Walstra

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Early Alzheimer’S Disease

Download Full-text

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Alzheimer s Research & Therapy ◽

10.1186/s13195-018-0415-6 ◽

2018 ◽

Vol 10 (1) ◽

Cited By ~ 24

Author(s):

Maarten Timmers ◽

Johannes Rolf Streffer ◽

Alberto Russu ◽

Yushin Tominaga ◽

Hiroko Shimizu ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Bace1 Inhibitor ◽

Early Alzheimer’S Disease

Download Full-text

INVOKE‐2: A phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer’s disease

Alzheimer s & Dementia ◽

10.1002/alz.054615 ◽

2021 ◽

Vol 17 (S9) ◽

Author(s):

Robert Paul ◽

Sam Jackson ◽

Michael Ward ◽

Aashka Joshi ◽

Abraham Castro ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Early Alzheimer’S Disease

Download Full-text

P3-033: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS TREATMENT OF BIIB092 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE: TANGO PHASE 2 STUDY DESIGN

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.1388 ◽

2006 ◽

Vol 14 (7S_Part_20) ◽

pp. P1077-P1077 ◽

Cited By ~ 1

Author(s):

Elena Ratti ◽

Bjoern Sperling ◽

Tina Olsson ◽

Li Zhang ◽

Kumar Kandadi Muralidharan ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Study Design ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Early Alzheimer’S Disease

Download Full-text

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Alzheimer s Research & Therapy ◽

10.1186/s13195-020-00614-5 ◽

2020 ◽

Vol 12 (1) ◽

Cited By ~ 3

Author(s):

Gerald Novak ◽

Johannes Rolf Streffer ◽

Maarten Timmers ◽

David Henley ◽

H. Robert Brashear ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Extension Study ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Bace1 Inhibitor ◽

Disease Spectrum ◽

Early Alzheimer’S Disease

Download Full-text

Faculty Opinions recommendation of Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1124846.581937 ◽

2008 ◽

Author(s):

Elio Scarpini ◽

Daniela Galimberti

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Activities Of Daily Living ◽

Daily Living ◽

Controlled Study ◽

Double Blind ◽

Global Function ◽

Double Blind Placebo

Download Full-text

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Alzheimer s Research & Therapy ◽

10.1186/alzrt146 ◽

2012 ◽

Vol 4 (5) ◽

pp. 43 ◽

Cited By ~ 230

Author(s):

John M Ringman ◽

Sally A Frautschy ◽

Edmond Teng ◽

Aynun N Begum ◽

Jenny Bardens ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

BMC Medical Genetics ◽

10.1186/1471-2350-12-137 ◽

2011 ◽

Vol 12 (1) ◽

Cited By ~ 21

Author(s):

Samuel T Henderson ◽

Judes Poirier

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Ketone Body ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study

Neurology ◽

10.1212/01.wnl.0000052994.54660.58 ◽

2003 ◽

Vol 60 (7) ◽

pp. 1071-1076 ◽

Cited By ~ 59

Author(s):

O.M. Wolkowitz ◽

J.H. Kramer ◽

V.I. Reus ◽

M.M. Costa ◽

K. Yaffe ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dhea Treatment

Download Full-text

DGAVP (Org 5667) in early Alzheimer's disease patients: An international double-blind, placebo-controlled, multicenter trial

Neurology ◽

10.1212/wnl.40.7.1099 ◽

1990 ◽

Vol 40 (7) ◽

pp. 1099-1099 ◽

Cited By ~ 10

Author(s):

E. Ch. Wolters ◽

P. Riekkinen ◽

A. Lowenthal ◽

J. J. V. der Plaats ◽

J.M.T. Zwart ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Multicenter Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Early Alzheimer’S Disease

Download Full-text